COMMUNIQUÉS West-GlobeNewswire

FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®
15/06/2017
FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus ® Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine Sandoz looks [...]
Solon Eiendom ASA - Primary insider notification
15/06/2017
SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 15 June 2017) Solon Eiendom ASA Board member Edvin Austbø (through his wholly owned company Alden AS) has [...]
Nestlé to explore strategic options for its US confectionery business
15/06/2017
This press release is also available in Français (pdf) and Deutsch (pdf) ....................................... Vevey, 15 June 2017 Nestlé to explore strategic options for its US confectionery business Nestlé will [...]
Solon Eiendom ASA - Primary insider notification
15/06/2017
SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 15 June 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company [...]
Participation de Nicox à la Convention Internationale BIO 2017
15/06/2017
Participation de Nicox à la Convention Internationale BIO 2017 15 juin 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société internationale de Recherche et [...]
Nicox to present at the 2017 BIO International Convention
15/06/2017
Nicox to present at the 2017 BIO International Convention June 15, 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Emmet [...]
ThromboGenics Long-time Non-executive Director Thomas Clay Appointed Chairman of the Board of Directors
15/06/2017
Leuven, Belgium, 15 June 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announces that the Board has appointed long-time non-executive [...]
Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of vested restricted stock units
15/06/2017
Lars Lund-Roland, member of the Board of Targovax ASA, has on 15 June 2017 subscribed for 16,394 shares in Targovax ASA at a price of NOK 0.10 per share in connection with settlement of vested restricted stock units (" [...]
RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection
15/06/2017
Subject to a successful outcome and any additional regulatory feedback, the confirmatory Phase III study (ERADICATE Hp 2) is expected to complete the package required for a potential U.S. NDA for RHB-105, newly branded [...]
Summit Therapeutics to Participate in JMP Securities Life Sciences Conference
15/06/2017
Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN JMP SECURITIES LIFE SCIENCES CONFERENCE Oxford, UK, 15 June 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug [...]
uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies
15/06/2017
-- Study published in Molecular Therapy provides proof of concept of successful cross-administration of AAV5- and AAV1-based gene therapies -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 15, 2017 (GLOBE [...]
NCSBN CEO Benton Receives Great Cross of Spanish Nursing from the Spanish General Council of Nursing
15/06/2017
CHICAGO, June 15, 2017 (GLOBE NEWSWIRE) -- NCSBN CEO David Benton, RGN, PhD, FFNF, FRCN, FAAN, received the Great Cross of Spanish Nursing in the Gold Category from the Spanish General Council of Nursing in Barcelona, [...]
Pöyry and Betulium sign co-operation agreement to unlock full value chain benefits for clients in bio-based businesses
15/06/2017
Pöyry and Betulium have signed a Letter of Intent (LOI) for co-operation that will enable both companies to serve their clients better in bio-based businesses. Pöyry and Betulium share common objectives in bioindustry: [...]
Zealand increases its share capital as a consequence of exercise of employee warrants
15/06/2017
Copenhagen, June 15, 2017 - Zealand Pharma ("Zealand") has increased its share capital by a nominal amount of DKK 8,537 divided into 8,537 new shares with a nominal value of DKK 1 each. The increase is a consequence of [...]
ESPERITE (ESP): L1 Capital subscribes to the third packed tranche of investment today
15/06/2017
Zutphen, The Netherlands, 15 June 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a third Packed Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]
Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
15/06/2017
Cosentyx ® is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] Additional data show rapid and sustained pain [...]
TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn's Disease and Ulcerative Colitis
15/06/2017
PRESS RELEASE TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn's Disease and Ulcerative Colitis - Joins the Crohn's and Colitis Foundation's President's Corporate Circle - Signs [...]
INNATE PHARMA : Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102
15/06/2017
DOSE-ESCALATION DATA SHOW favorable SAFETY PROFILE AND PROMISING CLINICAL ACTIVITY FOR IPH4102 Oral presentation on the dose-escalation part of a Phase I trial at the International Conference on Malignant Lymphoma (ICML [...]
INNATE PHARMA : Résultats d'escalade de dose d'IPH4102 : Profil de tolérance et activité clinique prometteurs
15/06/2017
rÉsultats d'escalade de dose d'IPH4102 : profil de tolÉrance et activitÉ clinique prometteurs La partie en escalade de dose de l'essai de Phase I a fait l'objet d'une présentation orale lors de l'ICML [1] à Lugano ; [...]

Pages